Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

XenoPort Announces Presentations at the American Academy of Neurology Meeting

XenoPort Inc.
Posted on: 18 Mar 13

XenoPort Inc. (Nasdaq: XNPT) announced today that it will present the following posters at the 65th Annual Meeting of the American Academy of Neurology in San Diego California:

AP (arbaclofen placarbil)Spasticity

  • An Ongoing Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity Due to Multiple SclerosisSession Info: Poster Session P03: March 19 2:00 pm - 6:30 pm PTPoster #: P03.267
  • The Burden of Multiple Sclerosis-Related Spasticity on Indirect Costs and Requirement for Non-Professional Care: Results of a Cross-Sectional Study in the USASession Info: Poster Session P03: March 19 2:00 pm - 6:30 pm PTPoster #: P03.217
  • Impact of Spasticity on Healthcare Resource Utilisation: Results of a Cross-Sectional Study in the USASession Info: Poster Session P03: March 19 2:00 pm - 6:30 pm PTPoster #: P03.211

XP1279Parkinson’s Disease

  • Double-Blind Study of an Actively-Transported Levodopa Prodrug XP21279 in Parkinson DiseaseSession Info: Poster Session P02: March 19 7:30 am – 12:00 pm PTPoster #: P02.075

XP23829Preclinical and Phase 1 Studies

  • Comparative Gastric Irritation of the Fumaric Acid Esters Dimethyl Fumarate (DMF) and XP23829 in Rat and MonkeySession Info: Poster Session P01: March 18 2:00 pm - 6:30 pm PTPoster #: P01.159
  • Favorable Metabolism and Pharmacokinetics of Formulations of XP32829 a Novel Fumaric Acid Ester in Healthy SubjectsSession Info: Poster Session P05: March 20 2:00 pm – 7:00 pm PTPoster #: P05.189

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended Release Tabletsis our first approved product in the United States. GlaxoSmithKline holds commercialization rights for Horizant in the United States during a transition period ending on April 30 2013 following which XenoPort will be responsible for the further development manufacturing and commercialization of Horizant. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity Parkinson's disease relapsing-remitting multiple sclerosis and/or psoriasis.

To learn more about XenoPort please visit the web site at

Horizant Regnite and XENOPORT are registered trademarks of XenoPort Inc.

Source code: XNPT2C

Business Wire

Last updated on: 18/03/2013

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.